Patents by Inventor Salvatore Demartis

Salvatore Demartis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11905232
    Abstract: The disclosure provides a process for the preparation of 3-(4?-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: February 20, 2024
    Assignee: Nogra Pharma Limited
    Inventors: Salvatore Demartis, Francesca Viti, Marie McNulty
  • Publication number: 20230234963
    Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.
    Type: Application
    Filed: July 7, 2022
    Publication date: July 27, 2023
    Inventors: Francesca Viti, Salvatore Bellinvia, Salvatore Demartis
  • Publication number: 20230212582
    Abstract: The present disclosure relates to compositions of oligonucleotide (e.g., SMAD7 antisense oligonucleotide diastereomers) and methods of manufacturing, assessing efficacy, and using the compositions.
    Type: Application
    Filed: April 23, 2021
    Publication date: July 6, 2023
    Inventors: Francesca Viti, Giovanni Monteleone, Salvatore Demartis, Salvatore Bellinvia, Marie McNulty
  • Patent number: 11427600
    Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: August 30, 2022
    Assignee: Nogra Pharma Limited
    Inventors: Francesca Viti, Salvatore Bellinvia, Salvatore Demartis
  • Publication number: 20220194894
    Abstract: The disclosure provides a process for the preparation of 3-(4?-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
    Type: Application
    Filed: February 10, 2020
    Publication date: June 23, 2022
    Inventors: Salvatore Demartis, Francesca Viti, Marie McNulty
  • Publication number: 20170158707
    Abstract: The present invention is generally directed towards compounds capable of binding the aryl hydrocarbon receptor and modulating its activity, methods of treating inflammatory conditions such as Crohn's disease using such compounds, and pharmaceutical compositions comprising such compounds. Also provided are methods of increasing levels of IL-22 in a subject and/or decreasing levels of IFN-? in a subject.
    Type: Application
    Filed: June 26, 2015
    Publication date: June 8, 2017
    Inventors: Francesca Viti, Salvatore Bellinvia, Salvatore Demartis
  • Patent number: 8664381
    Abstract: The present invention relates to a process for the purification of amorolfine hydrochloride by means of a reversed-phase preparative high performances liquid chromatography (prep-HPLC) said method starting from a crude Amorolfine hydrochloride having purity higher than 90% and containing Bepromoline hydrochloride <5% and Fenpropimorf <3%. The process involves the use of a mobile phase comprising water and an organic solvent under isocratic conditions.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: March 4, 2014
    Assignee: SYNTECO S.p.A.
    Inventors: Roberto Angeli, Marco Possenti, Salvatore Demartis
  • Patent number: 8242262
    Abstract: A process is described for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group, products useful as photosensitizing agents in photodynamic therapy.
    Type: Grant
    Filed: May 4, 2006
    Date of Patent: August 14, 2012
    Assignee: L. Molteni & C. Dei Fratelli Alitti Societa'di Esercizio S.p.A.
    Inventors: Donata Dei, Giacomo Chiti, Daniele Nistri, Gabrio Roncucci, Aldo Hendrikus Velders, Salvatore Demartis, Valentina Paschetta
  • Publication number: 20110301346
    Abstract: The present invention relates to a process for the purification of amorolfine hydrochloride by means of a reversed-phase preparative high performances liquid chromatography (prep-HPLC) said method starting from a crude Amorolfine hydrochloride having purity higher than 90% and containing Bepromoline hydrochloride <5% and Fenpropimorf <3%. The process involves the use of a mobile phase comprising water and an organic solvent under isocratic conditions.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 8, 2011
    Applicant: SYNTECO S.P.A.-PRODOTTI DI SINTESI PER L'INDUSTRIA CHIMICA E FARMACEUTICA
    Inventors: Roberto Angeli, Marco Possenti, Salvatore Demartis
  • Publication number: 20090131393
    Abstract: A process is described for preparing chlorides of phthalocyanine derivatives comprising at least a quaternary ammonium group, products useful as photosensitising agents in photodynamic therapy.
    Type: Application
    Filed: May 4, 2006
    Publication date: May 21, 2009
    Applicant: L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A.
    Inventors: Donata Dei, Giacomo Chiti, Daniele Nistri, Gabrio Roncucci, Aldo Hendrikus Velders, Salvatore Demartis, Valentina Paschetta
  • Patent number: 6495673
    Abstract: A method for isolating the DNA encoding an enzyme is presented. The DNA is contained within a support to which the enzyme is linked, wherein the enzyme is further linked to a substrate. When the enzyme reacts with the substrate, the product remains linked to the enzyme. The product linked to the enzyme which is linked to the support containing the DNA encoding the enzyme is isolated, thereby isolating the DNA encoding the enzyme. In this manner an expression library of enzymes produced by mutagenesis can be screened for mutated active enzyme, and thereby obtain the mutated DNA encoding the mutated active enzyme.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: December 17, 2002
    Assignee: Medical Research Council
    Inventors: Dario Neri, Salvatore Demartis, Adrian Huber, Francesca Viti, Dan S Tawfik, Gregory Paul Winter
  • Patent number: 6184012
    Abstract: The present invention relates to a method of isolating an enzyme having a desired chemical or biological activity, the method comprising linking the enzyme to a substrate for the enzyme, reacting the enzyme and substrate such that a product is produced which remains linked to the enzyme and isolating the enzyme by selectively isolating the product linked to the enzyme.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: February 6, 2001
    Assignee: Medical Research Council
    Inventors: Dario Neri, Salvatore Demartis, Adrian Huber, Francesca Viti, Dan S Tawfik, Gregory Paul Winter